Veradermics (MANE) Income towards Parent Company (2025 - 2026)
Veradermics (MANE) posted Income towards Parent Company of -$27.2 million for Q1 2026, down 119.61% on a QoQ basis from -$12.4 million in Q1 2025, and down 119.61% year-over-year from $138.8 million in Q1 2025.
Veradermics (MANE) Income towards Parent Company (2025 - 2026) Analysis & Trends
Veradermics' Income towards Parent Company history runs 2 years deep, the most recent figure standing at -$27.2 million for Q1 2026.
- Quarterly Income towards Parent Company fell 119.61% year-over-year to -$27.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$39.6 million (changed N/A YoY) and the FY2025 annual result came in at -$70.0 million, down 164.25% from the prior year.
- Income towards Parent Company was -$27.2 million for Q1 2026 at Veradermics, down from -$12.4 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$12.4 million in Q1 2025 and bottomed at -$27.2 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Veradermics | 2.55 Bn | 2.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.23 Mn |
| Mar 31, 2025 | -12.40 Mn |